Company intelligence / Profile preview
iTheranostics
Dover, Delaware, United Statessofie.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
iTheranostics developed a library of fibroblast activation protein (FAP) targeting agents, including FAPI-46 and FAPI-74, for radiopharmaceutical imaging and therapy. The company licensed global therapeutic rights of these compounds to Novartis for clinical development, while retaining responsibilities for commercializing imaging tracers. The clinical stage of the compounds themselves in Novartis's hands is not public, but as of the deal, they were pre-clinical to early clinical.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalRadioligandSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
NovartisUniversity of Heidelberg (original IP licensor)
Beyond the preview
Go deeper on iTheranostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iTheranostics.